SMT201600431B - Proteine β-glucocerebrosidasi ricombinanti, varianti, con aumentata stabilità e aumentata attività catalitica conservata - Google Patents

Proteine β-glucocerebrosidasi ricombinanti, varianti, con aumentata stabilità e aumentata attività catalitica conservata

Info

Publication number
SMT201600431B
SMT201600431B SM201600431T SM201600431T SMT201600431B SM T201600431 B SMT201600431 B SM T201600431B SM 201600431 T SM201600431 T SM 201600431T SM 201600431 T SM201600431 T SM 201600431T SM T201600431 B SMT201600431 B SM T201600431B
Authority
SM
San Marino
Prior art keywords
increased
recombinant
variants
catalytic activity
glucocerebrosidase proteins
Prior art date
Application number
SM201600431T
Other languages
English (en)
Italian (it)
Inventor
Hung Do
Original Assignee
Callidus Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Callidus Biopharma Inc filed Critical Callidus Biopharma Inc
Publication of SMT201600431B publication Critical patent/SMT201600431B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SM201600431T 2010-11-08 2016-11-24 Proteine β-glucocerebrosidasi ricombinanti, varianti, con aumentata stabilità e aumentata attività catalitica conservata SMT201600431B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41133110P 2010-11-08 2010-11-08
US41218010P 2010-11-10 2010-11-10
PCT/US2011/059731 WO2012064709A2 (en) 2010-11-08 2011-11-08 Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity

Publications (1)

Publication Number Publication Date
SMT201600431B true SMT201600431B (it) 2017-01-10

Family

ID=46051505

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600431T SMT201600431B (it) 2010-11-08 2016-11-24 Proteine β-glucocerebrosidasi ricombinanti, varianti, con aumentata stabilità e aumentata attività catalitica conservata

Country Status (19)

Country Link
US (4) US8962564B2 (cg-RX-API-DMAC10.html)
EP (2) EP2638152B1 (cg-RX-API-DMAC10.html)
JP (2) JP6073796B2 (cg-RX-API-DMAC10.html)
KR (1) KR101901467B1 (cg-RX-API-DMAC10.html)
CN (2) CN105296447A (cg-RX-API-DMAC10.html)
BR (1) BR112013011152A2 (cg-RX-API-DMAC10.html)
CA (1) CA2817011C (cg-RX-API-DMAC10.html)
CY (1) CY1118843T1 (cg-RX-API-DMAC10.html)
DK (1) DK2638152T3 (cg-RX-API-DMAC10.html)
ES (2) ES2743825T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20161560T1 (cg-RX-API-DMAC10.html)
HU (1) HUE030932T2 (cg-RX-API-DMAC10.html)
LT (1) LT2638152T (cg-RX-API-DMAC10.html)
PL (1) PL2638152T3 (cg-RX-API-DMAC10.html)
PT (1) PT2638152T (cg-RX-API-DMAC10.html)
RS (1) RS55405B1 (cg-RX-API-DMAC10.html)
SI (1) SI2638152T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201600431B (cg-RX-API-DMAC10.html)
WO (1) WO2012064709A2 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157248A1 (en) * 2019-02-01 2020-08-06 Oxyrane Uk Ltd Glucocerebrosidase polypeptides
CN113795575A (zh) 2019-02-04 2021-12-14 自由行疗法有限公司 多核苷酸
US20220325265A1 (en) 2019-09-09 2022-10-13 Hoffmann-La Roche Inc. Glucocerebrosidase mutants
WO2021199039A1 (en) * 2020-03-29 2021-10-07 Yeda Research And Development Co. Ltd. Variants of beta-glucocerebrosidase for use in treating gaucher disease
KR20230042513A (ko) * 2020-07-29 2023-03-28 프리라인 테라퓨틱스 리미티드 폴리펩티드
WO2023145814A1 (ja) * 2022-01-31 2023-08-03 株式会社日本触媒 向上した酵素活性または向上した安定性を有する組換えグルコセレブロシダーゼタンパク質
JPWO2023145813A1 (cg-RX-API-DMAC10.html) * 2022-01-31 2023-08-03
WO2023145812A1 (ja) * 2022-01-31 2023-08-03 株式会社日本触媒 グルコセレブロシダーゼ活性を有する糖鎖付加タンパク質
WO2023198661A1 (en) 2022-04-12 2023-10-19 F. Hoffmann-La Roche Ag Fusion proteins targeted to the central nervous system
CN121406674A (zh) * 2022-10-08 2026-01-27 凌意(杭州)生物科技有限公司 用于治疗GCase缺乏相关疾病的多核苷酸
AU2024394235A1 (en) * 2023-12-08 2026-06-11 Denali Therapeutics Inc. Modified glucocerebrosidase polypeptides and methods of use thereof
TW202617982A (zh) * 2024-06-24 2026-05-01 美商戴納立製藥公司 包含經修飾之葡萄糖腦苷脂酶多肽之融合蛋白及其方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03503721A (ja) * 1988-12-23 1991-08-22 ジェンザイム コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
JP2893481B2 (ja) 1988-12-23 1999-05-24 ジェンザイム コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
NZ500694A (en) 1997-04-30 2001-09-28 Univ Minnesota Use of chimeric mutational vector (CMV), a macromolecule and a ligand for cell surface receptor adhesion molecule (clatherin) in gene therapy; the CMV vector derived from REC2 homologous pairing with Ustilago maydis
EP1027069B1 (en) * 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
IL141403A0 (en) 1998-08-28 2002-03-10 Univ Duke Deleted adenoviruses and methods of making and administering the same
IL150314A0 (en) 1999-12-30 2002-12-01 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
IL152110A0 (en) 2000-04-06 2003-07-31 Exegenics Inc Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase)
AU2001267337A1 (en) * 2000-06-30 2002-01-14 Maxygen Aps Peptide extended glycosylated polypeptides
US7855063B2 (en) * 2003-04-16 2010-12-21 Yeda Research And Development Co. Ltd. Partially deglycosylated glucocerebrosidase polypeptide and crystals thereof
WO2005089047A2 (en) 2004-03-18 2005-09-29 Glycofi, Inc. Glycosylated glucocerebrosidase expression in fungal hosts
AU2008245578A1 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
KR101789000B1 (ko) * 2007-05-22 2017-10-20 아미쿠스 세라퓨틱스, 인코포레이티드 이소파고민과 이의 유도체를 제조하는 새로운 방법
US9150849B2 (en) 2007-11-02 2015-10-06 The Scripps Research Institute Directed evolution using proteins comprising unnatural amino acids
EP2220218A4 (en) 2007-11-02 2010-12-08 Scripps Research Inst GENETICALLY ENCODED BORONATE AMINO ACID

Also Published As

Publication number Publication date
HRP20161560T1 (hr) 2016-12-30
CY1118843T1 (el) 2018-01-10
KR20140009238A (ko) 2014-01-22
US9566316B2 (en) 2017-02-14
US8962564B2 (en) 2015-02-24
WO2012064709A3 (en) 2012-08-02
US20150216950A1 (en) 2015-08-06
US20170157220A1 (en) 2017-06-08
EP2638152B1 (en) 2016-08-31
RS55405B1 (sr) 2017-04-28
US20160184408A1 (en) 2016-06-30
EP3144386A1 (en) 2017-03-22
US9254313B2 (en) 2016-02-09
JP2017099390A (ja) 2017-06-08
JP6073796B2 (ja) 2017-02-01
US9821038B2 (en) 2017-11-21
JP2014500722A (ja) 2014-01-16
CA2817011C (en) 2019-04-02
BR112013011152A2 (pt) 2016-11-29
EP3144386B1 (en) 2019-05-29
CA2817011A1 (en) 2012-05-18
KR101901467B1 (ko) 2018-11-02
ES2604490T3 (es) 2017-03-07
PT2638152T (pt) 2016-10-25
CN103314105B (zh) 2015-11-25
WO2012064709A2 (en) 2012-05-18
JP6457559B2 (ja) 2019-01-23
US20130344054A1 (en) 2013-12-26
HUE030932T2 (en) 2017-06-28
EP2638152A2 (en) 2013-09-18
SI2638152T1 (sl) 2016-12-30
PL2638152T3 (pl) 2017-02-28
CN105296447A (zh) 2016-02-03
ES2743825T3 (es) 2020-02-20
DK2638152T3 (en) 2016-12-12
LT2638152T (lt) 2016-12-12
EP2638152A4 (en) 2014-04-09
CN103314105A (zh) 2013-09-18

Similar Documents

Publication Publication Date Title
IL280949A (en) Ph20 polypeptide variants, formulations and uses thereof
PL2638152T3 (pl) Warianty rekombinowanych białek beta-glukocerebrozydaz ze zwiększoną stabilnością i zwiększoną zachowaną aktywnością katalityczną
BRPI1010957A2 (pt) variantes de celulase com expressão, atividade e/ou estabilidade aprimorada e uso das mesmas.
IL262976B (en) Medicinal lysosomal enzyme chimeric proteins and their uses
DK2603596T3 (da) Sammensætninger, som omfatter et polypeptid med cellulolyseforbedrende aktivitet og en væske, og anvendelser deraf
BR112013021524A2 (pt) micro-organismos recombinantes e usos dos mesmos
DK2337796T3 (da) Rekombinante proteiner, som har hæmostatisk aktivitet og er i stand til at inducere trombocytaggregation
PT3434775T (pt) Proteína que tem atividade de nuclease, proteínas de fusão e utilizações das mesmas
NL301156I2 (nl) Recombinant eiwit CCE uit Streptococcus equi, recombinant eiwit Eq85 uit Streptococcus equi, en recombinant eiwit IdeE uit Streptococcus equi
IT1398316B1 (it) Struttura di ruota piroettante, particolarmente per mobili e simili.
HUE057894T2 (hu) Alfa-amiláz változatok javított aktivitással keményítõpolimereken
DK2473494T3 (da) Polypeptider med oxidoreduktaseaktivitet og anvendelser deraf
PL2588492T3 (pl) Polipeptyd mający aktywność beta-glukozydazy i jego zastosowania
LT3473714T (lt) Polipeptidai, pasižymintys transgalaktozilinimo aktyvumu
WO2013091897A8 (en) Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
WO2011143511A3 (en) Methods for producing enteroendocrine cells that make and secrete insulin
ZA201108577B (en) Cellulase variants with improved expression, activity and/or stability, and use thereof
IL232645B (en) Recombinant proteins and their therapeutic uses
DK3392268T3 (da) Polypeptider med transgalactosylerende aktivitet
EP2742069A4 (en) AMPHIPATHIC PEPTIDE LIPASE CONJUGATE WITH ADVANCED LIPASE ACTIVITY AND USE THEREOF
DK2049092T3 (da) Præparater med forbedret elastiserende aktivitet
BRPI0907700A2 (pt) Imidazopiridazinas como inibidores par1, produção das mesmas e uso como medicamentos
DK2152881T3 (da) RumC-peptider med antimikrobiel aktivitet
EP2216402A4 (en) USE OF ACTIVE RECOMBINANT CHYMOSINE
HK1189624A (en) Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity